Atle Fund Management AB Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001381843

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q3 2026 · 39 positions · Total reported value $373.39M · Top-10 concentration 53.9% · Updated 2026-11-12

Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR

Turnover: 53.5% · 4 new · 15 cut · 4 exited

Active Share (vs S&P 500): 94.8% · vs QQQ: 98.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -10.0% · vs SPY -12.1% · Prev Value $371.70M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): +5.6% · vs SPY +3.4% · Latest Value $373.39M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Atle Fund Management AB disclosed 39 equity positions with a combined reported value of $373.39M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 53.9% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were LLY ($36.10M), MRK ($24.56M), JNJ ($24.19M). By sector, the heaviest allocations are Health Care 90.6%, Industrials 6.2%. Versus the prior quarter, allocation shifted toward Industrials (+2.5pp) and away from Consumer Staples (-0.9pp), Health Care (-1.6pp).

Versus the prior quarter, Atle Fund Management AB opened 4 new positions, trimmed 15 and fully exited 4, a turnover rate of 53.5% of positions. The portfolio's overlap with the prior quarter was 81% of names.

The largest new positions opened in Q3 2026 were SMMT ($3.12M), CMPS ($3.03M), PVLA ($2.06M).

Of the 4 positions fully exited versus the prior quarter, the largest were IONS ($10.87M), BCAX ($4.32M), CMPX ($2.30M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • SMMT SUMMIT THERAPEUTICS INC · $3.12M
  • CMPS COMPASS PATHWAYS PLC · $3.03M
  • PVLA Palvella Therapeutics Inc · $2.06M
  • MANE Veradermics, Incorporated · $1.23M

Fully Exited (vs previous quarter)

  • IONS IONIS PHARMACEUTICALS INC · prev qtr: $10.87M
  • BCAX Bicara Therapeutics Inc · prev qtr: $4.32M
  • CMPX COMPASS THERAPEUTICS INC · prev qtr: $2.30M
  • JBIO JADE BIOSCIENCES INC · prev qtr: $1.97M

Insider Transactions (Form 4)

Latest Atle Fund Management AB buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Atle Fund Management AB files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 39 positions worth $371.70M in total. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).

Portfolio Structure

  • 39 positions · $371.70M reported value (Q2 2026)
  • Top 10 holdings = 48.0% of reported value
  • Largest position: LLY (ELI LILLY & CO) at 9.6%
  • Average position size: $9.53M

Sector Tilt

  • Health Care 92.2%
  • Consumer Staples 4.1%
  • Industrials 3.8%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 3 new, 16 added, 20 reduced, 3 exited

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is actively increasing exposure to healthcare (70% of top-10 holdings), particularly biotech/pharma, while modestly reducing some positions, suggesting a bullish stance on healthcare innovation and selective profit-taking. 2. Key moves: - Added: JNJ (+0.64% wt), ABBV (+2.04% wt), TMO (+2.46% wt), BIIB (+0.64% wt), VRTX (+1.38% wt), ONC (+0.80% wt). - Reduced: MRK (-0.03% wt), RVMD (-0.05% wt), CVS (-0.87% wt). 3. Portfolio structure: Active, concentrated (39 positions), with heavy healthcare bias (90% of top-10) and high risk appetite (biotech/tech focus). 4. Per-holding one-liner: - LLY (Eli Lilly: diabetes/obesity drugs), MRK (Merck: oncology/immunology), JNJ (Johnson & Johnson: healthcare/pharma), ABBV (AbbVie: immunology/oncology), TMO (Thermo Fisher: lab equipment), BIIB (Biogen: neurology), VRTX (Vertex: cystic fibrosis), RVMD (Revolution Medicines: cancer), ONC (Beone Medicines: oncology), CVS (CVS Health: retail pharmacy). 5. Style summary: Aggressive healthcare tilt with biotech conviction, selectively trimming winners to fund new bets.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-13 03:24

Sector Allocation

Health Care 90.6%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 31.20K $36.10M 9.67%
9.67%
Add
2 168.99K $24.56M 6.58%
6.58%
Reduce
3 91.39K $24.19M 6.48%
6.48%
Add
4 91.29K $23.88M 6.40%
6.40%
Add
5 34.41K $23.23M 6.22%
6.22%
Add
6 70.95K $16.03M 4.29%
4.29%
Add
7 28.16K $14.72M 3.94%
3.94%
Add
8 66.11K $13.57M 3.63%
3.63%
Reduce
9 35.68K $13.06M 3.50%
3.50%
Add
10 139.31K $11.94M 3.20%
3.20%
Reduce
11 36.11K $10.84M 2.90%
2.90%
Add
12 163.70K $10.77M 2.88%
2.88%
Add
13 25.65K $10.43M 2.79%
2.79%
Add
14 87.47K $9.98M 2.67%
2.67%
Add
15 109.65K $9.46M 2.54%
2.54%
Add
16 34.30K $9.44M 2.53%
2.53%
Add
17 77.38K $9.39M 2.52%
2.52%
Add
18 28.07K $9.34M 2.50%
2.50%
Add
19 89.25K $7.70M 2.06%
2.06%
Add
20 303.82K $7.39M 1.98%
1.98%
Add
21 54.10K $6.15M 1.65%
1.65%
Hold
22 40.46K $6.03M 1.61%
1.61%
Reduce
23 70.07K $5.99M 1.60%
1.60%
Reduce
24 26.73K $5.95M 1.59%
1.59%
Add
25 130.62K $5.70M 1.53%
1.53%
Reduce
26 136.22K $5.52M 1.48%
1.48%
Reduce
27 38.61K $5.48M 1.47%
1.47%
Reduce
28 184.39K $4.60M 1.23%
1.23%
Reduce
29 46.45K $4.60M 1.23%
1.23%
Reduce
30 44.24K $3.94M 1.05%
1.05%
Reduce
31 43.18K $3.60M 0.96%
0.96%
Reduce
32 93.55K $3.59M 0.96%
0.96%
Reduce
33 184.69K $3.12M 0.84%
0.84%
New
34 243.51K $3.03M 0.81%
0.81%
New
35 43.68K $2.86M 0.77%
0.77%
Hold
36 29.89K $2.38M 0.64%
0.64%
Reduce
37 14.92K $2.06M 0.55%
0.55%
New
38 663.77K $1.55M 0.41%
0.41%
Reduce
39 10.11K $1.23M 0.33%
0.33%
New

FAQ

What did Atle Fund Management AB buy in 2026-Q3?

In its 2026-Q3 13F filing, Atle Fund Management AB reported 39 equity positions worth $373.39M in aggregate; its largest disclosed positions were LLY ($36.10M), MRK ($24.56M), JNJ ($24.19M).

How large is Atle Fund Management AB's portfolio?

Atle Fund Management AB reported $373.39M of long equity holdings across 39 positions as of 2026-Q3. Top-10 holdings account for 53.9% of reported value.

What is Atle Fund Management AB's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/atle-fund-management-ab/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →